Quality of life is an important end point in clinical trials, and it is important to discuss that with regulatory agencies, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Quality of life is an important end point in clinical trials, and it is important to discuss that with regulatory agencies, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Transcript
For myeloproliferative neoplasms, why is quality of life not used as much as an end point?
Quality of life as an end point is certainly something that's evolving in cancer and in the blood diseases overall. In myeloproliferative neoplasms [MPNs], in many ways they've now become a leader in this regard. When we started this journey back in the mid-2000s, before the first testing with the JAK inhibitors, [quality of life was] pretty much was not looked at it in any disease. Now, we had worked to develop the instruments, the myelofibrosis symptom assessment form, as well as the MPN symptom assessment form that now have become the standard particularly for phase 3 clinical trials.
Now, usually the end point that's included in studies is actual symptom improvement. There have been much discussion with the regulatory bodies regarding the different between the 2, but at least now, actual very specific symptoms, such as itching, such as night sweats, you know can now be quantified at least in a subjective way with a validated instruments with improvement, then potentially as an end point.
There's even studies now that have it as either a coprimary, or even a primary end point. Quality of Life, I think is a very important secondary end point. Part of even health-related quality of life has many aspects, which include in financial toxicity and other things that perhaps are still more nuanced. But I think they are important, without question discussions with the regulatory agencies that are very sensitive to clinical benefit as being important for patients, and quality of life, of course, is an important distillation of clinical benefit.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More